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Summary: Galanthamine, physostigmine and 9-amino-l,2,3,4-tetrahydroacridine (tacrine) were evaluated s
inhibitors of human acetylcholinesterase activity from samples of postmortem human brain, fresh brain cortex
biopsies and human erythrocytes. Acetylcholinesterase activity was most effectively inhibited in all tissues by
physostigmine, followed by tacrine and galanthamine. The respective inhibitor concentrations exerting a half
maximal effect (IC50) on acetylcholinesterase in postmortem human brain frontal cortex were 14nmol/l,
1.0 μιηοΐ/ΐ and 3.2 μηιόΐ/ΐ versus 15 nmol/1, 1.1 μτηοΐ/ΐ and 2.8 μιηοΐ/ΐ in the hippocampus region. In addition,
the Inhibition of acetylcholinesterase by galanthamine was similar in postmortem brain and brain cortical
biopsies from patients submitted to brain-tumour removal, indicating that postmortem changes up to 28 h
after death probably did not influence the measurement of acetylcholinesterase Inhibition. While physostigmine
and tacrine acted equally on acetylcholinesterase from different sources, galanthamine was 10-fold less potent
in inhibiting the enzyme activity from human brain than from human erythrocytes. Comparison with issues
from mice revealed that galanthamine was selectively more potent in suppressing acetylcholinesterase in human
erythrocytes. The results are discussed in the light of pharmacokinetic data, and conclusions are drawn for
further clinical studies.
in Alzheimer's disease were determined: the frontal
Reversible cholinesterase inhibitors are currently used cortex and the hippocampus. Since measurement of
for symptomatic treatment of cognitive deficits and red-cell acetylcholinesterase Inhibition ex vivo may
memory impairment in Alzheimer's disease. One pos- predict enzyme Inhibition in the brain (6, 7), it seemed
tulated mechanism is restoration of the cholinergic useful to perform additional in vitro experiments with
deficit at synaptic sites in the brain by inhibition of erythrocytes. Postmortem acetylcholinesterase activ-
acetylcholine metabolisipti (1), b t severalother mech^ ity has been shown to be stable (8) for at least 31 h.
anisms have also been discussed (2 — 5). It was the It has also been reported, however, that the 4S and
purpose of this study to measure the inhibition of 10S molecular forms in the brain are extremely labile
acetylcholinesterase1) from various sources by galan- and that freezing of either subcellular or intact tissue
thamine, physostigmine and tacrine. A series of con- causes dramatic shifts in the level of the molecular
centration response trials was performed using human forms (9), although the molecular shift was not as-
brain tissue; and, prior to further specified analysis soeiated with any change of total acetylcholinesterase
currently in progress, two separate regions of interest activity. To identify possible alterations in postmor-
tem tissue, the inhibition of acetylcholinesterase by
1) Enzymes: Acetyl holinesterase, EC 3.1.1.7 galanthamine in fresh human brain cortex samples
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obtained at biopsies in 4 patients during brain-tumour
ablation was also studied. In addition, the inhibitory
effects of galanthamine, physostigmine and tacrine on
acetylcholinesterase in vitro were also measured in
erythrocytes and fresh brain tissue samples of animals.
Materials and Methods
Postmortem human brain tissue from the frontal cortex and
hippocampal region of 11 individuals without evidence of psy-
chiatric illnesses (7 female, 4 male, age 56-87) was dissected
5-28 h after death, frozen and stored at -70 °C until exami-
nation. Neuropathological examination of matching samples
ensured that the patients showed no evidence of specific neu-
rological il iess. Fresh surgical samples of human cortex were
obtained from 4 patients where such tissue was removed to
gain access to the tumour (10). The non-tumorous (peritumo-
rous) tissue was irnmediately frozen and stored s described
above. Aliquots of laboratory routine whole blood samples
were taken from the same patients prior to the surgical proce-
dure, centrifuged and the red cells separated. Adult male
NMRI-mice (bred by the Bundesgesundheitsamt Berlin and
kept under standardized conditions) were killed by decapita-
tion; trunk blppd was collected in heparinized plastic tubes and
mixed immediately. Whole blood was centrifuged, and the red
cells were separated s above. Erythrocytes were haemolysed
by freezing and thawing 3 times using liquid nitrogen. Brain
samples were weighed and homogenized using an Ultra Turrax
(Janke und Kunkel, Staufen, Germany) for 20 s at 20 000 min"1
in 3 volumes of ice-cold S renserfs phosphate buffer. The cata-
lytic activity of acetylcholinesterase in erythrocytes and brain
was measured s previously described in detail (11, 12), using
[14C]acetylcholine iodide (NEN, Dreieich, Germany) radiola-
belled in the acetyl moiety at a final Substrate concentration of
3.6 mmol/1, a pH of 7.4 and a temperature of 25 °C. Concen-
tration response trials were performed s previously described
(11, 12). The Inhibitors used were galanthamine (Nivalin™,
Waldheim, Vienna, Austria), tetraisopropylpyrophosphoramide
(iso-OMPA, Sigma, Deisenhofen, Germany), physostigmine
(Serva, Heidelberg, Germany) and tacrine (Serva, Heidelberg,
Germany). After incubation of the sample with the inhibitor
for 60 min at 25 °C in vitro, the catalytic reaction was started
by the addition of Substrate.
Statistical Analysis
Calculations were performed using the statistical programs 'Stat
5.3' by Gary Perlman, University of California, San Diego, and
a non-linear regression program by Koeppe & Hamann (13)
based on the least squares method, which was run on a Siemens
MX-2 microcomputer. The concentrations required to achieve
20-80% Inhibition of the enzyme activity were calculated from
the fitted concentration response using an empirically modified
HUI equation with the following set of parameters:
/ = • + d · log c + e
Results
Butyrylcholinesterase activity was selectively inhibited
by 0.1 mmol/1 tetraisopropylpyrophosphoramide in
some samples of postmortem human brain cortex and
hippocampus; this did not inhibit acetylcholinesterase
in the assay used, s demonstrated in earlier investl··
gations (11), or change the concentration response of
total cholinesterase activity to galanthamine, physo-
stigmine and tacrine, indicating that the catalytic ac-
tivity of cholinesterase in the human brain samples
was almost completely related to acetylcholinesterase
activity. To avoid interactions
 fbetween tetraisopro-
pylpyrophosphoramide and a second inhibitor, the
subsequent concentration-response trials were per-
formed without specific Inhibition of butyrylcholines-
terase activity.
Assays of frontal cortex and hippocampal samples
revealed 2- to 3-fold higher acetylcholinesterase activ-
ities in the latter, s reported by other authors (8,14).
No significant diffefences, however, were seen be-
tween the two regions with respect to the inhibition
of acetylcholinesterase activity by galanthamine, phy-
sostigmine or tacrine (fig. 1; tab. 1). Acetylcholi es-
terase activity in the human brain frontal cortex tissue
obtained at autopsy was inhibited over a r nge of
20-80% most effectively by physostigmine (3-74
nmol/1), followed by tacrine at between 210 nmol/1
and 4.0 μπιοΐ/ΐ and galanthamine at between 650
nmol/1 and 17.8 μηιοΙ/1 (fig. 1; tab. 1). Human brain
temporal cortex tissue and the frontal cortex hpiiip-
genate showed identical Inhibition by physostigmine
(fig. 1; tab. 2). Comparison of fresh brain cortex
biopsies with postmortem cortex tissue revealed the
same inhibitory response to galanthamine. Red-cell
cholinesterase activity in blood samples from the neu-
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Fig. 1. Co centrations of between l mnol/1 and 0.1 mmol/1 of
galanthamine (V, T), physostigmine (o, ·, a), and
tacrine (Ο, φ) were incubated for l h at 25 °C in vitro
with samples of human brain cortex of the frontal (o,
O, V) or temporal (φ) fegion and human brain hip*
poc mpus (D, φ, Τ) before the reaction was started
by adding Substrate. Values represent the mean inhibi-
tion in postmortem homogenate samples from 6^11
different patients at autopsy with less than 28 h delay.
Mean values were derived from the averages of d plidate
assays. » i
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Tab. 1. Inhibition of acetylcholinesterase activity in human brain tissue
Tissue n Inhibitor Inhibitor concentration [nmol/1]
Frontal
Cortex
Hippo-
campus
Frontal
Cortex
Hippo-
campus
Frontal
Cortex
Hippo-
campus
1 5 10 25
9 Physostigmine 6.2 29.8 40.3 65.2
(2.4) (1.6) (2.7) (1.2)
10 Physostigmine 10.6 24.2 43.6 60.5
(2.0) (2.7) (2.3) (2.8)
9 Tacrine —0.7
(0.7)
10 Tacrine 4.8
(3.5)
1 1 Galanthamine 5.6
(4.9)
10 Galanthamine 0.0
(2.5)
-1.1
(5.1)
2.4
(2.9)
-2.3
(3.8)
2.2
(2.5)
50 100
73.7 83.6
(2.4) (2.2)
76.9 86.0
(1.9) (2.5)
12.9
(2.0)
13.4
(1-5)
4.9
(2.1)
7.3
(2.8)
500
35.7
(1-9)
32.1
(2.6)
16.7
(2.7)
18.1
(2.2)
1000
94.8
(2.4)
93.9
(1.4)
49.9
(2.8)
51.2
(2.5)
27.7
(2.1)
29.9
(1.4)
5000
84.2
(2.9)
76.8
(3.1)
59.0
(2.8)
66.8
(2.0)
10000 50000
95.8
(2.0)
93.1 92.5
(3.9) (2.3)
85.7 97.2
(1-8) (2.5)
71.9
(1.5)
68.3
(4.0)
100000
106
(7.6)
94.3
(1.6)
91.5
(1.1)
93.1
(1.1)
Concentration response for Inhibition by l nmol/1 to 0.1 mmol/1 of physostigmine, tacrine and galanthamine, which were incubated
for l h at 25 °C in vitro with n different samples of postmortem human brain tissue. Mean values of enzyme Inhibition (% of
uninhibited control) and the Standard error of the mean (in brackets) are given.
rosurgery patients, however, was 10 times more
strongly inhibited by galanthamine than the respective
enzyme activity in brain tissue samples. This intrain-
dividual comparison reflected the same differences äs
those between human postmortem brain tissue and
acetylcholinesterase inhibition in red cells of 8 healthy
male volunteers of an earlier trial ((12); fig. 2). In
contrast to galanthamine, each of the cholinesterase
inhibitörs, physostigmine and tacrine, diminished en-
zyme activities in human brain tissue and human
erythrocytes to the same degree. Concentrations of
the inhibitörs exerting a half-maximal effect (ICso
values) on acetylcholinesterase of varioüs sources are
summarized in table 2. Evaluation of acetylcholines-
terase activity in the brain cortex homogenate and
erythrocytes of NMRI-mice resulted in a slope of the
concentration response curve, which was flatter than
that in human tissues, äs described above. However,
the red cells and brain of NMRI-mice showed no
relevant differences in acetylcholinesterase inhibition
(fig. 3; tab. 2).
Discussion
In this study, physostigmine was found to be more
potent than tacrine and galanthamine in suppressing
cholinesterase activity in the human brain. The data
correspond very well to those of a similar trial (5), in
Tab. 2. ICSO of varioüs acetylcholinesterase inhibitörs
Species
Human
Human
Human
Human
Human
Human
Mouse
Mouse
Group
Postmörtem
Postmortem
Ppstmprtem
Neurosurgery
Neürosurgery
Volunteer
Decapitation
Decapitation*
Tissue
Brain
Brain
Brain
Brain
Erythrocyte
Erythrocyte
Brain
Erythrocyte
Region
Hippo-
campus
Frontal
Cortex
Temporal
Cortex
Cortex
Cortex
(n)
(10)
(9)
(6)
(7)
(5)
(5)
Physo-
stigmine
15
14
16
27
63
68
(n)
(10)
(9)
(8)
(5)
(5)
Tacrine
1070
950
1590
1290
1230
(n)
(10)
(H)
(4)
(4)
(8)
(5)
(5)
Galan-
thamine
2750
3240
2900
370
360
4400
5100
Physostigmine, tacrine and galanthamine were incubated for l h at 25 °C in vitro with n different samples of varioüs tissues. The
inhibitor cpncentrations (nmol/1) producing a half-maximal effect (ICso) on acetylcholinesterase were derived from a plot of %
enzyme inhibition versus log concentration of inhibitor.
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Fig. 2. Comparison of the inhibitory effects of galanthamine
on acetylcholinesterase activity in human brain tissue
and human erythrocytes in vitro. Human brain tissue
was obtained at autopsy less than 28 h postmortem from
2 regions, frontal cortex (D) and hippocampus (o), or
äs fresh tissue during neurosurgical removal (O) of a
braih «tumour. Human red cells were obtained from
healthy volunteers (B) and the respective neurosurgical
patients (O) before the induction of anaesthesia. Assay
conditions äs stated in figure 1. Values represent the
mean Inhibition of 4 (neurosurgery group), 10—11
(postmortem group), and 7 or 8 (volunteers) samples.
which Perry and colleagues used physostigmine and
tacrine in samples of postmortem parietal cortex ob-
tained after an equal autopsy delay from 3 individuals
with no clinical or pathological evidence of any neu-
rological or psychiatric disorder. There are minor
differences between the two reports, i. e. they found
tacrine to be 1.5 times more and physostigmine 2
times less potent than we did. Both cholinesterase
inhibitors have been widely used in vivo, but relatively
few studies have reported plasma/serum concentra-
tions of physostigmine (15-17) or tacrine (18-20).
The doses were increased until adverse peripheral
effects in the majority of the respective patients or
volunteers indicated the upper tolerance level. These
concentrations were in the ränge of 11-25 nmol/1
with physostigmine (15) and 60-220 nmol/1 with
tacrine (18). Peak galanthamine concentrations after
intravenous application of 0.3 mg/kg body weight in
anaesthetized patients were 1890 nmol/1 (21), while
drug concentrations in plasma 2 h after chronic oral
administration of 15 mg three times daily in Alzheimer
patients (22) were in the ränge of 400-550 nmol/1.
According to our data (fig. 1; tab. 1; tab. 2), these
measured plasma concentrations would not result in
high degrees of central cholinesterase inhibition. It
has been reported, however, that galanthamine, phy-
sostigmine and tacrine accumulate in the brain tissue
of small animals. If this occurs to an equal extent in
Fig. 3- Concentrations of between 0.5 nmol/1 and 0.5 mmol/1
of galanthamine (p, p), physostigmine (o, o) and tac-
rine ( , ) were incubated fpr l h at 25 °C in vitro
with samples of NNlRI^mice brain cortex (open sym-
bols) and erythrocytes (filled Symbols). Values represent
the mean of n = 5 different samples.
humans, physostigmine might be increased 2-fold (23,
24) and tacrine 8 —12-fold (25), resulting in an esti-
mated acetylcholinesterase inhibition of 65% and
75% respectively. In the case of galanthamine (26),
the accumulation factor of 2 would only lead to a
25 — 35% enzyme inhibition in the human brain. This
finding may be explained by the fact that galantham-
ine, in contfast to physostigmine and tacrine, was
markedly less potent in suppressing acetylcholinester-
ase activity in the human brain than in human red
cells. One might speculate whether galanthamine sep-
arated between different moleculär G-forms of ace-
tylcholinesterase (erythrocytes dimeric; brain tetra-
meric), while physpstigmine and tacrine did not, äs
was recently shown for the Gt and G4 form using the
latter 2 compounds (27). There were no differences in
enzyme inhibition by galanthamine, physostigmine
and tacrine, however, between erythrocytes and brain
tissue of mice.
In vitro measurement of cholinesterase inhibition in
tissue homogenates may not reliably reflect true drug
concentrations, true inhibition of acetylcholinesterase
activity or in vivo alterations at synaptic sites in the
brain. In addition, the rate of appearance and the
effects of various metabolites of the cholinesterase
inhibitors are still unclear. Moreover, it has been
reported that, in Alzheimer patients, the location of
cholinesterases has largely shifted to the neüritic
plaqües and tangles (28), giving rise to the speculation
that cholinesterase-inhibiting dfugs may act differ-
ently in an Alzheimer brain than in a nön-diemented
one. And finally, although there is some evidence on
the relationship between oAzyme inhibition and
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 29,1991 / Np. 8
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changes in acetylcholine content or turnover (25, 29,
30), the degree of acetylcholinesterase Inhibition re-
quired to elicit central effects in the human brain is
still unknown.
Despite all of these serious limitations, some conclu-
sions, however, may be drawn from the current data:
1. Inhibition of catalytic enzyme activity in erythro-
cytes, äs rneasured ex vivo in the patient, is a fairly
close predictor of cholinesterase Inhibition in the brain
if physostigmine or tacrine have been given. The
measurement of peripheral acetylcholinesterase activ-
ity after galanthamine application may be used äs a
safety parameter and estimate of central Inhibition.
2. Clinical studies on the efficacy of reversible cholin-
esterase inhibitors should employ an individual dose
finding phase according to the report of a consensus
Conference on the methodology of clinical trials of
"nootropics" (31) and, in addition, include the con-
comitant degree of ex vivo enzyme Inhibition. The
lower doses of galanthamine, physostigmine and tac-
rine used so far in many clinical studies possibly did
not cause the anticipated degrees of Inhibition of brain
acetylcholinesterase activity, and this would explain
in part the limited effect.
3. Ex vivo measurement of enzyme Inhibition should
be performed äs soon äs possible during clinical in-
vestigation to verify the in vitro findings.
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